Lupin Limited has informed the Exchange regarding a press release dated May 07, 2026, titled "Lupin FY2026 and Q4 FY2026 Results".

Revenue Growth 20pctPat Growth 25pctEbitda Margin ExpansionExceptional ItemResults View source PDF Explain this filing

LUPIN · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

-3.6%Reaction day

₹2462.00

prior close

₹2425.00

announcement price

After-mkt

timing

Nifty Midcap 150market · index membership as recorded later (tracked since Jun 2026)-0.1%-3.5% vs market

Pharmaceuticals peers, median of 161sector+0.1%-3.7% vs sector

On the reaction day the stock moved 3.5 pts less than Nifty Midcap 150 and 3.7 pts less than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

+0.6

10m

+2.0

15m

+1.6

30m

-0.3

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

-3.6-0.1-3.5+0.1-3.7

Next day

-8.9-1.2-7.7+0.2-9.1

-8.6-3.7-4.9-1.4-7.2

-9.8-3.1-6.7-1.9-7.9

-8.5-2.0-6.6-1.6-7.0

-7.2-2.4-4.8-1.7-5.6

-6.9-1.9-5.0-2.0-4.9

15d

-8.4-2.4-6.1-0.7-7.8

-8.7-3.9-4.8-1.5-7.2

-0.2-1.2+1.0+3.4-3.6

-6.6+2.9-9.5+5.9-12.5

UpDownMarket · Nifty Midcap 150Sector · Pharmaceuticals peers, median of 161Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Lupin Limited reported strong full-year FY2026 results with sales up 23.9% to INR 2,74,875 Mn and PAT surging 62% to INR 53,555 Mn. EBITDA margin expanded significantly by 890 basis points to 33.6%, driven by robust performance in the U.S. market (up 46% for full year) and overall margin improvement. Q4 FY2026 was particularly strong with sales of INR 73,919 Mn (up 32.9% YoY) and PAT of INR 14,687 Mn (up 87.7% YoY). The company received 3 ANDA approvals during the quarter and has 151 generic products in the U.S. market. Exceptional items of INR 5,579 Mn (net) were recorded for the year. The Board recommended a dividend of 900%.

Likely market impact

The results demonstrate strong operational performance with margin expansion and robust profit growth, indicating improved profitability and market position, particularly in the U.S. business. The strong PAT growth and cash generation (net debt of INR -46,358 Mn) are positive for shareholders.